News

The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.

Oxford Biotherapeutics Relocates Its UK Base to the Oxford Science Park, Aiming to Accelerate the Development of Immuno-oncology and ADC-based Cancer Treatments

Thursday, October 12, 2023

Oxford BioTherapeutics Ltd OBT a clinicalstage oncology company specializing in immunooncology and antibodydrug conjugate ADCbased therapies has relocated its UK headquarters to The Schrodinger Building within The Oxford Science Park

Salipro Biotech and Icosagen Announce a Collaboration for Antibody Discovery

Wednesday, October 11, 2023

Salipro Biotech AB a Swedish biotech company and Icosagen an Estonian biotechnology company have recently announced their collaboration in a multitarget antibody research agreement aimed at advancing drug discovery programs focused on challenging mem...

Scorpion Therapeutics and Pierre Fabre Laboratories Initiate Phase 1/2 Clinical Trial

Wednesday, October 11, 2023

Scorpion Therapeutics Inc and Pierre Fabre Laboratories have jointly announced the commencement of a Phase clinical trial for STX a groundbreaking tyrosine kinase inhibitor tailored to target epidermal growth factor receptor EGFR and ERBB HER Exon...

Valo Therapeutics Acquires Bruker Corporation's Latest Mass Spectrometer Platform for Tumor Antigen Identification Through Valotx's Peptichip Technology

Wednesday, October 11, 2023

Valo Therapeutics Oy ValoTx has made a significant announcement as the first European biotech company to incorporate the Bruker Corporations cuttingedge timsTOF Ultra mass spectrometer and liquid chromatography platform into its operations

RAD Granted Approval for Phase 1 Clinical Trial of PDL1-Nanobody in Non-Small Cell Lung Cancer

Tuesday, October 10, 2023

Radiopharm Theranostics ASXRAD has obtained approval from the Human Research Ethics Committee HREC to initiate its Phase I study in Australia marking the first human trials for the companys therapy designed to treat patients with PDLpositive nonsmall...

FDA Grants Orphan Drug Designation to Ultimovacs' UV1 Vaccine for Mesothelioma Treatment

Monday, October 09, 2023

Ultimovacs ASA OSE ULTI a prominent biotechnology company specializing in innovative cancer vaccines has secured Orphan Drug Designation ODD from the US Food and Drug Administration FDA for their therapeutic cancer vaccine UV intended for the treatme...

FDA Approves Arcutis' ZORYVE® (Roflumilast) Cream 0.3% for Psoriasis Treatment in Children Ages 6 to 11

Saturday, October 07, 2023

Arcutis Biotherapeutics Inc NASDAQ ARQT is an early commercialstage biopharmaceutical company with a focus on advancing innovations in immunodermatology

Abbvie Exercises Exclusive Option to Acquire Mitokinin, Enhancing Its Neuroscience Pipeline

Friday, October 06, 2023

AbbVie NYSE ABBV has officially acquired Mitokinin a biotech firm in the discovery phase which has been working on a pioneering treatment for Parkinsons Disease PD

BIOVECTRA and Acuitas Therapeutics Enter Into Partnership for Unique Lipid Nanoparticle (LNP) Delivery System in the Production of MRNA-based Therapies

Friday, October 06, 2023

BIOVECTRA and Acuitas Therapeutics Inc have announced a collaborative technology transfer service agreement BIOVECTRA will gain access to Acuitas advanced Lipid Nanoparticle LNP technology platform for manufacturing mRNAbased therapeutics on a nonexc...

Ankyra Therapeutics Enters Clinical Trial Collaboration and Supply Deal with Merck to Assess ANK-101 Alongside KEYTRUDA® in Advanced Solid Tumor Patients

Thursday, October 05, 2023

Ankyra Therapeutics a clinical biotechnology company specializing in the development of a unique form of localized immunotherapy known as anchored immunotherapy has announced a collaboration and supply agreement for a clinical trial with Merck known...